Hemab Therapeutics Holdings IPO: offering terms from its S-1
Hemab Therapeutics Holdings priced its IPO at $18 a share on 1 May 2026 and raised $302 million. Its shares trade on Nasdaq as COAG.
Headlines
- Net loss, 2025
- $64M
- IPO price
- $18
- $302M raised
Hemab Therapeutics Holdings IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- COAG
- IPO price
- $18
- Shares offered
- 16,750,000
- Raised
- $302M
- Registered
- $311M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies and Evercore ISI
- First filed
- 10 Apr 2026
Hemab Therapeutics Holdings revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$70M | -$64M |
Hemab Therapeutics Holdings share structure and company facts
- Employees
- 72
- Headquarters
- Cambridge, MA
Hemab Therapeutics Holdings shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 1 May 2026
- First close
- $34.00
- +89% on the IPO price
- Latest close
- $36.02
- +100% on the IPO price
Hemab Therapeutics Holdings' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Hemab Therapeutics Holdings' newest prospectus (424B4 filed 1 May 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.